<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265145</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0064</org_study_id>
    <nct_id>NCT03265145</nct_id>
  </id_info>
  <brief_title>Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]</brief_title>
  <official_title>Randomized Pragmatic Clinical Trial in a Community-Based Setting Comparing STIOLTO® RESPIMAT® vs. ICS-LABA Plus LAMA in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Healthcore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pragmatic study is to compare the time to first moderate or
      severe COPD exacerbation in patients, not controlled on their current therapy, randomized to
      Stiolto Respimat versus triple therapy over 12 months of treatment

      The secondary objectives of this study include:

        1. To compare the annual rate of moderate or severe COPD exacerbations for patients on
           Stiolto Respimat with patients on triple therapy.

        2. To compare the time to first severe COPD exacerbation in both treatment arms.

        3. To compare the annual rate of severe COPD exacerbations in both treatment arms.

        4. To compare the proportion of patients with moderate or severe COPD exacerbations in both
           treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">June 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe chronic obstructive pulmonary disease (COPD) exacerbation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual rate of severe chronic obstructive pulmonary disease (COPD) exacerbations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Stiolto Respimat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ICS plus LABA plus LAMA (triple therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stiolto Respimat</intervention_name>
    <description>Duration - 12 months</description>
    <arm_group_label>Stiolto Respimat</arm_group_label>
    <other_name>INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICS (Inhaled Corticosteroid) (Triple therapy)</intervention_name>
    <description>Duration - 12 months</description>
    <arm_group_label>ICS plus LABA plus LAMA (triple therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA (Long-Acting Beta Agonist) (Triple therapy)</intervention_name>
    <description>Duration - 12 months</description>
    <arm_group_label>ICS plus LABA plus LAMA (triple therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)</intervention_name>
    <description>Duration - 12 months</description>
    <arm_group_label>ICS plus LABA plus LAMA (triple therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD diagnosis as defined by the study physician

          -  Currently on one of the following maintenance therapies:

               -  LAMA monotherapy

               -  LABA monotherapy

               -  ICS/LABA (FDC)

          -  Physician determination that patient is not controlled on current pharmacotherapy

          -  Adult patient 40 years of age or older at time of study enrollment

          -  Willingness and ability to understand and provide documented Informed Consent Form
             (ICF) and Health Insurance Portability and Accountability Act (HIPAA) Authorization
             Form prior to commencement of any study required assessments, either directly or
             through Legally Authorized Representative.

        Exclusion Criteria:

          -  Currently on LAMA/LABA (free or FDC) or triple therapy (ICS plus LABA plus LAMA)

          -  Contraindication to any study medications (LAMA, LABA or ICS)

          -  Documented diagnosis of current asthma

          -  Pregnant or nursing women

          -  Women of childbearing potential are not restricted in this trial, however it is
             expected that the investigator will assess the risks and benefits of the assigned
             treatment as per the product label(s) and discuss this with any women of childbearing
             potential prior to providing the patient with the prescription for the assigned
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Newport Native MD, Inc</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Klein</last_name>
      <phone>+001 (949) 791-8599</phone>
      <email>ryan@newportnativemd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital Allergy and Respiratory Disease Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Parikh</last_name>
      <phone>+001 (916) 233-2628</phone>
      <email>nparikh@capitalallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonology, Sleep, Asthma and Allergy Center of Dublin</name>
      <address>
        <city>Dublin</city>
        <state>Georgia</state>
        <zip>31021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vishal Agrawal</last_name>
      <phone>+001 (478) 272-3209</phone>
      <email>agrawav@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Lung Specialists, PC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Tarirah</last_name>
      <phone>+001 (478) 745-9998</phone>
      <email>geraldtarira@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DC Pulmonary Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binu George</last_name>
      <phone>+001 (770) 419-0020</phone>
      <email>binugeorgemd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Smits</last_name>
      <phone>+001 (260) 432-5005</phone>
      <email>theaacfw@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The LaPorte County Institute for Clinical Research</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ikeadi Ndukwu</last_name>
      <phone>+001 (219) 728-8261</phone>
      <email>indukwu@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisville Pulmonary Care</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Haller</last_name>
      <phone>+001 (502) 899-7377</phone>
      <email>hdhjrmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Paul A. Shapero</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Shapero</last_name>
      <phone>+001 (207) 947-8658</phone>
      <email>allergyme@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advance Clinical Research Inc</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brij Vaid</last_name>
      <phone>+001 (314) 256-9990</phone>
      <email>clinicaltrials@acrtc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Sigal</last_name>
      <phone>+001 (336) 659-6414</phone>
      <email>bsigal@salemchest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schear</last_name>
      <phone>+001 (937) 609-3677</phone>
      <email>mschear@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Pulmonary and Sleep Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Yunger</last_name>
      <phone>+001 (937) 380-7063</phone>
      <email>jamieyunger@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep and Pulmonary Center</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Margolis</last_name>
      <phone>+001 (937) 836-5356</phone>
      <email>rmargo@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Bedel</last_name>
      <phone>+001 (937) 746-4505</phone>
      <email>gary_bedel@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Medicine</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Renston</last_name>
      <phone>+001 (216) 297-3168</phone>
      <email>jpr2@case.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Incorporated</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navin Jain</last_name>
      <phone>+001 (419) 479-5864</phone>
      <email>njain@toledoclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research, LLC</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Bertsch</last_name>
      <phone>+001 (440) 221-4409</phone>
      <email>bertsch_j@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Brockmyre</last_name>
      <phone>+001 (423) 999-2415</phone>
      <email>andrew.brockmyre@myhmg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Family Practice</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Maughan</last_name>
      <phone>+001 (804) 358-0258</phone>
      <email>george.maughan@hcahealthcare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscarinic Antagonists</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

